410 related articles for article (PubMed ID: 20428688)
61.
Elena Ferreira M; Rojas de Arias A; Yaluff G; Vera de Bilbao N; Nakayama H; Torres S; Schinini A; Torres S; Serna E; Torrecilhas AC; Fournet A; Cebrián-Torrejón G
Nat Prod Res; 2019 Nov; 33(22):3308-3311. PubMed ID: 29745731
[TBL] [Abstract][Full Text] [Related]
62. Pentamidine antagonizes the benznidazole's effect in vitro, and lacks of synergy in vivo: Implications about the polyamine transport as an anti-Trypanosoma cruzi target.
Seguel V; Castro L; Reigada C; Cortes L; Díaz MV; Miranda MR; Pereira CA; Lapier M; Campos-Estrada C; Morello A; Kemmerling U; Maya JD; López-Muñoz R
Exp Parasitol; 2016 Dec; 171():23-32. PubMed ID: 27729250
[TBL] [Abstract][Full Text] [Related]
63. Biological factors that impinge on Chagas disease drug development.
Francisco AF; Jayawardhana S; Lewis MD; Taylor MC; Kelly JM
Parasitology; 2017 Dec; 144(14):1871-1880. PubMed ID: 28831944
[TBL] [Abstract][Full Text] [Related]
64. Aetiological treatment with itraconazole or ketoconazole in individuals with Trypanosoma cruzi/HIV co-infection.
de Almeida EA; Silva EL; Guariento ME; Aoki FH; Pedro Rde J
Ann Trop Med Parasitol; 2009 Sep; 103(6):471-6. PubMed ID: 19695152
[TBL] [Abstract][Full Text] [Related]
65. In vivo and in vitro auranofin activity against Trypanosoma cruzi: Possible new uses for an old drug.
da Silva MT; Silva-Jardim I; Portapilla GB; de Lima GM; Costa FC; Anibal Fde F; Thiemann OH
Exp Parasitol; 2016 Jul; 166():189-93. PubMed ID: 26183422
[TBL] [Abstract][Full Text] [Related]
66. Characteristics of Patients for Whom Benznidazole Was Released Through the CDC-Sponsored Investigational New Drug Program for Treatment of Chagas Disease - United States, 2011-2018.
Herwaldt BL; Dougherty CP; Allen CK; Jolly JP; Brown MN; Yu P; Yu Y
MMWR Morb Mortal Wkly Rep; 2018 Jul; 67(29):803-805. PubMed ID: 30048425
[TBL] [Abstract][Full Text] [Related]
67. Hit-to-lead optimization of novel 2-alkylaminomethylquinoline derivatives as anti-chagas agents.
Muscia GC; Roldán Pacheco FJ; Asís SE; Buldain GY; Frank FM
Eur J Med Chem; 2020 Jan; 186():111877. PubMed ID: 31771829
[TBL] [Abstract][Full Text] [Related]
68. Trypanosoma cruzi: Induction of benznidazole resistance in vivo and its modulation by in vitro culturing and mice infection.
Dos Santos FM; Caldas S; de Assis Cáu SB; Crepalde GP; de Lana M; Machado-Coelho GL; Veloso VM; Bahia MT
Exp Parasitol; 2008 Dec; 120(4):385-90. PubMed ID: 18823980
[TBL] [Abstract][Full Text] [Related]
69. A cysteine protease inhibitor cures Chagas' disease in an immunodeficient-mouse model of infection.
Doyle PS; Zhou YM; Engel JC; McKerrow JH
Antimicrob Agents Chemother; 2007 Nov; 51(11):3932-9. PubMed ID: 17698625
[TBL] [Abstract][Full Text] [Related]
70. Evaluation of the in vivo therapeutic properties of (-)-cubebin and (-)-hinokinin against Trypanosoma cruzi.
Esperandim VR; da Silva Ferreira D; Rezende KC; Cunha WR; Saraiva J; Bastos JK; e Silva ML; de Albuquerque S
Exp Parasitol; 2013 Apr; 133(4):442-6. PubMed ID: 23274812
[TBL] [Abstract][Full Text] [Related]
71. Current status of Chagas disease chemotherapy.
Guedes PM; Silva GK; Gutierrez FR; Silva JS
Expert Rev Anti Infect Ther; 2011 May; 9(5):609-20. PubMed ID: 21609270
[TBL] [Abstract][Full Text] [Related]
72. Anti-T. cruzi agents: our experience in the evaluation of more than five hundred compounds.
Cerecetto H; González M
Mini Rev Med Chem; 2008 Nov; 8(13):1355-83. PubMed ID: 18991753
[TBL] [Abstract][Full Text] [Related]
73. Trypanocidal treatment of Chagas disease.
Pérez-Molina JA; Crespillo-Andújar C; Bosch-Nicolau P; Molina I
Enferm Infecc Microbiol Clin (Engl Ed); 2021 Nov; 39(9):458-470. PubMed ID: 34736749
[TBL] [Abstract][Full Text] [Related]
74. Efficacy of novel benznidazole solutions during the experimental infection with Trypanosoma cruzi.
Manarin R; Lamas MC; Bottasso E; Serra E; Revelli S; Salomón CJ
Parasitol Int; 2013 Feb; 62(1):79-81. PubMed ID: 22975280
[TBL] [Abstract][Full Text] [Related]
75. Drug discovery for Chagas disease should consider Trypanosoma cruzi strain diversity.
Zingales B; Miles MA; Moraes CB; Luquetti A; Guhl F; Schijman AG; Ribeiro I; ;
Mem Inst Oswaldo Cruz; 2014 Sep; 109(6):828-33. PubMed ID: 25317712
[TBL] [Abstract][Full Text] [Related]
76. In Vitro and In Vivo Trypanosomicidal Action of Novel Arylimidamides against Trypanosoma cruzi.
Guedes-da-Silva FH; Batista DG; Meuser MB; Demarque KC; Fulco TO; Araújo JS; Da Silva PB; Da Silva CF; Patrick DA; Bakunova SM; Bakunov SA; Tidwell RR; Oliveira GM; Britto C; Moreira OC; Soeiro MN
Antimicrob Agents Chemother; 2016 Apr; 60(4):2425-34. PubMed ID: 26856830
[TBL] [Abstract][Full Text] [Related]
77. Clear Shot at Primary Aim: Susceptibility of Trypanosoma cruzi Organelles, Structures and Molecular Targets to Drug Treatment.
Menna-Barreto RF; de Castro SL
Curr Top Med Chem; 2017; 17(10):1212-1234. PubMed ID: 27784255
[TBL] [Abstract][Full Text] [Related]
78. Trypanocidal drugs for chronic asymptomatic Trypanosoma cruzi infection.
Villar JC; Marin-Neto JA; Ebrahim S; Yusuf S
Cochrane Database Syst Rev; 2002; (1):CD003463. PubMed ID: 11869663
[TBL] [Abstract][Full Text] [Related]
79. New Approaches for the Treatment of Chagas Disease.
Pandey RP; Nascimento MS; Moore CE; Raj VS; Kalil J; Cunha-Neto E
Curr Drug Targets; 2021; 22(7):835-841. PubMed ID: 33238855
[TBL] [Abstract][Full Text] [Related]
80. Antitrypanosomal Activity of Sterol 14α-Demethylase (CYP51) Inhibitors VNI and VFV in the Swiss Mouse Models of Chagas Disease Induced by the Trypanosoma cruzi Y Strain.
Guedes-da-Silva FH; Batista DG; Da Silva CF; De Araújo JS; Pavão BP; Simões-Silva MR; Batista MM; Demarque KC; Moreira OC; Britto C; Lepesheva GI; Soeiro MN
Antimicrob Agents Chemother; 2017 Apr; 61(4):. PubMed ID: 28167559
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
